{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:44:46Z","timestamp":1754160286921,"version":"3.41.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10532-z","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:30:05Z","timestamp":1748662205000},"page":"1127-1131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Iron repletion in heart failure: a symptomatic win, a survival miss"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2958-943X","authenticated-orcid":false,"given":"Luca","family":"Monzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baljash","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"10532_CR1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ejhf.640","volume":"19","author":"V Melenovsky","year":"2017","unstructured":"Melenovsky V, Petrak J, Mracek T et al (2017) Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail 19:522\u2013530. https:\/\/doi.org\/10.1002\/ejhf.640","journal-title":"Eur J Heart Fail"},{"key":"10532_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","volume":"7","author":"S von Haehling","year":"2019","unstructured":"von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD (2019) Iron deficiency in heart failure: an overview. JACC Heart Fail 7:36\u201346. https:\/\/doi.org\/10.1016\/j.jchf.2018.07.015","journal-title":"JACC Heart Fail"},{"key":"10532_CR3","doi-asserted-by":"publisher","unstructured":"Nemeth E, Ganz T (2021) Hepcidin-Ferroportin interaction controls systemic iron homeostasis. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22126493","DOI":"10.3390\/ijms22126493"},{"key":"10532_CR4","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"key":"10532_CR5","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M et al (2023) 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44:3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"10532_CR6","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1016\/j.jacc.2024.03.431","volume":"83","author":"B Cheema","year":"2024","unstructured":"Cheema B, Chokshi A, Orimoloye O, Ardehali H (2024) Intravenous iron repletion for patients with heart failure and iron deficiency: JACC state-of-the-art review. J Am Coll Cardiol 83:2674\u20132689. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.431","journal-title":"J Am Coll Cardiol"},{"key":"10532_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.3833","author":"SD Anker","year":"2025","unstructured":"Anker SD, Friede T, Butler J et al (2025) Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.3833","journal-title":"JAMA"},{"key":"10532_CR8","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"10532_CR9","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC et al (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199\u20132209. https:\/\/doi.org\/10.1016\/S0140-6736(22)02083-9","journal-title":"Lancet"},{"key":"10532_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Garg J, Rockhold FW et al (2023) Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med 389:975\u2013986. https:\/\/doi.org\/10.1056\/NEJMoa2304968","journal-title":"N Engl J Med"},{"key":"10532_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03671-1","author":"SD Anker","year":"2025","unstructured":"Anker SD, Karakas M, Mentz RJ et al (2025) Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03671-1","journal-title":"Nat Med"},{"key":"10532_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ejhf.2860","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker SD, Khan MS, Butler J et al (2023) Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis. Eur J Heart Fail 25:1080\u20131090. https:\/\/doi.org\/10.1002\/ejhf.2860","journal-title":"Eur J Heart Fail"},{"key":"10532_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.2810","volume":"25","author":"FJ Graham","year":"2023","unstructured":"Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF (2023) Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail 25:528\u2013537. https:\/\/doi.org\/10.1002\/ejhf.2810","journal-title":"Eur J Heart Fail"},{"key":"10532_CR14","doi-asserted-by":"publisher","unstructured":"Camilli M, Ballacci F, Rossi VA, Cannat\u00e0 A, Monzo L, Mewton N, Girerd N, Gentile P, Marini M, Mapelli M, Flammer AJ, Aspromonte N, Montone RA, Lombardo A, Lanza GA, Savarese G, Ruschitzka F, Crea F\u00a0(2025) Iron deficiency and supplementation in patients with heart failure: results from the IRON-HF international survey. Eur J Heart Fail. 27(1):140\u2013147. https:\/\/doi.org\/10.1002\/ejhf.3356","DOI":"10.1002\/ejhf.3356"},{"key":"10532_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","volume":"11","author":"M Packer","year":"2023","unstructured":"Packer M (2023) Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. JACC Heart Fail 11:106\u2013114. https:\/\/doi.org\/10.1016\/j.jchf.2022.10.004","journal-title":"JACC Heart Fail"},{"key":"10532_CR16","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling S, Doehner W, Evertz R et al (2024) Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J 45:3789\u20133800. https:\/\/doi.org\/10.1093\/eurheartj\/ehae479","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10532-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10532-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10532-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T07:36:48Z","timestamp":1753515408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10532-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["10532"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10532-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"type":"electronic","value":"1573-7322"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"21 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Monzo reports travel grant from Boehringer. Dr. Cheema has received consulting fees from Caption Health, Inc and Viz.ai; has served on an Advisory Board for Novo Nordisk; and is an advisor with equity interest in Healthspan, Inc and Zoe Biosciences. Dr. Ambrosy has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (K23HL150159 and R01 AG091005), the American Heart Association (2nd Century Early Faculty Independence Award), The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Inc., Bayer, Cordio Medi- cal, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Dr. Girerd. reports honoraria from AstraZeneca, Bayer, Boehringer, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens.\u00a0Dr. Luca Monzo, Dr. Baljash Cheema, and Dr. Andrew P. Ambrosy are editorial board members for Heart Failure Reviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}